XXII
22nd Century Group IncKey Statistics
About 22nd Century Group Inc
22nd Century Group Inc (Ticker: XXII) is an innovative biopharmaceutical and agricultural company dedicated to tobacco harm reduction through advanced genetic engineering techniques. By focusing on the development of low-nicotine tobacco products, the firm aims to mitigate nicotine addiction while enhancing public health outcomes. As it strategically diversifies into the burgeoning hemp and cannabis markets, 22nd Century positions itself to capitalize on the expanding legal cannabis landscape. With a robust commitment to scientific research and adherence to regulatory frameworks, the company represents a compelling investment opportunity for institutional investors looking to engage in transformative sectors.
Fundamentals
| Revenue (TTM) | $5.20M |
| Gross Profit (TTM) | $-3.16M |
| EBITDA | $-10.83M |
| Operating Margin | -74.00% |
| Return on Equity | -103.60% |
| Return on Assets | -28.30% |
| Revenue/Share (TTM) | $15.68 |
| Book Value | $30.88 |
| Price-to-Book | 0.12 |
| Price-to-Sales (TTM) | 0.51 |
| EV/Revenue | 0.178 |
| EV/EBITDA | -0.47 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 80.40% |
| Shares Outstanding | $4.46M |
| Float | $4.07M |
| % Insiders | 0.42% |
| % Institutions | 1.90% |
Historical Volatility
Volatility is currently contracting